Severe Asthma, Ambiguous Biomarkers: Choosing a First Biologic Class
A patient whose eosinophils and exhaled nitric oxide both sit in a real but unremarkable middle zone, with no trial that has ever compared the three biologic mechanisms actually available to her.
Denise K. teaches choir at a public high school and times her own breathing during rehearsal warm-ups to the same four-count she gives her students — a trick that used to keep her asthma out of the way and now mostly just gets her through fourth period. She has had asthma since she was eleven, managed for most of that time with an inhaler and rarely a second thought, until this past year turned into three courses of oral steroids and a growing list of rehearsals she has had to sit out from the piano bench instead of the podium. Her regimen is already at its ceiling: high-dose inhaled corticosteroid with a long-acting beta-agonist, plus tiotropium added four months ago, and none of it has held.
Her labs land her in a real but ambiguous middle. A blood eosinophil count of 420/µL is elevated, but nowhere near the four-figure numbers that make an anti-IL5 case argue for itself, and an exhaled nitric oxide of 52 ppb is elevated enough to matter without being extreme. CHEST’s 2026 biologic guideline says plainly that evidence for choosing among mechanism classes here is limited by the absence of any trial comparing them head-to-head — and its own language leans on exactly the two numbers Denise has, describing dupilumab’s exacerbation benefit as rising in proportion to FeNO while noting that anti-IL5/5Rα agents have never been shown to move FeNO or use it to predict who actually responds. Omalizumab, the drug her allergy history would otherwise suggest first, is arithmetically out of reach: her IgE and body weight together fall outside what the dosing table permits. That leaves three real candidates and not one trial that ranks them against each other.
At the biologics clinic, three candidates and no comparison trial
Her FeNO is the number I would build the case around. CHEST’s own language on this is unusually direct for a guideline whose recommendations are otherwise conditional and very-low-certainty: the exacerbation benefit from dupilumab tracks proportionally with FeNO, and 52 ppb sits comfortably in the range where that relationship has actually shown up. Nothing about her eosinophil count argues against it either — 420 is well within dupilumab’s own approved range.
I would be making a different argument if her FeNO were unremarkable and her eosinophils were the only elevated number — that is a real anti-IL5 case, just not the one sitting in front of us.
I am not disputing the FeNO data, but I would weight it less than a proportional relationship in one guideline paragraph deserves. CHEST says it plainly: anti-IL5/5Rα and dupilumab have similar performance on the outcomes that actually matter, and choosing between them is a matter of secondary factors, not one drug having been demonstrated superior. Benralizumab has a longer real-world track record at her eosinophil level, and 420 is a number that mechanism was built to work on directly.
FeNO predicting who responds better to one drug is not the same claim as FeNO predicting who responds at all — and CHEST describes it as an association, not a rule that excludes the alternative.
Both of you are reading a genuinely ambiguous picture and resolving it toward the mechanism you would each have reached for anyway. Her numbers are not a clean case for either — 420 eosinophils and 52 FeNO are both real and both modest, which is exactly the profile where betting the whole decision on one biomarker’s proportional relationship carries the most risk if that relationship turns out not to hold for her specifically. Tezepelumab does not require choosing which single number to trust, which matters more here than it would in a patient whose numbers actually pointed one direction.
Agreed within the visit: start dupilumab, loading dose today, continue the existing high-dose ICS-LABA-tiotropium regimen unchanged underneath it.
Not fully agreed, and carried forward rather than smoothed over: how strictly to hold to CHEST’s own written switching threshold. The pulmonologist wants a hard rule — no clinical response by four to six months means an automatic switch to benralizumab, no extension — while acknowledging that CHEST’s own post-treatment FeNO threshold of 25 ppb is written for the reverse move, from anti-IL5/5Rα toward dupilumab, and so gives him no numeric trigger running in this direction. The allergist wants room to extend the trial if Denise is improving on every measure except that one number, arguing a guideline threshold built for group-level decisions should not override a genuinely improving individual patient. Left for the four-month visit, not resolved today.